| INTRODUCTION
Mortality and morbidity remain high in patients with chronic heart failure (HF), despite treatment with contemporary evidence-based pharmacotherapy. So there is a clinical need for new agents that will further improve long-term prognosis of chronic HF patients. It is demonstrated that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly referred to as statins, which is the key enzyme in the mevalonate pathway, protects against the development of HF by improving contractile function. [4] [5] [6] Our previous study confirmed rosuvastatin could improve cardiac dysfunction and found the molecular mechanism was related to the normalization of SERCA2a expression, SERCA activity, and phospho-phospholamban at serine-16 (PSer16-PLB) levels. 7 As we know, statins inhibit small GTPases (Ras, RhoA, Rac1) activity through reducing farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) generation in mevalonate pathway. 8 The role of mevalonate pathway in ischemic-induced HF and regulation of Ca 2+ handling proteins remains largely unknown. Existing data suggest SERCA2a gene expression could be suppressed by contractile activity via RhoA-ROCK-dependent transcription modulation in neonatal ventricular cardiomyocytes. 9 Also Rad (Ras associated with diabetes)
serves as an endogenous regulator of cardiac excitation-contraction coupling. 10, 11 In a recent in vitro study, we demonstrated that inhibition of the mevalonate pathway could ameliorate anoxia-mediated Ca
2+
handling dysfunction with the up-regulated expression of FKBP12.6
via RhoA-and Ras-related signaling pathways in H9c2 cells. 12 This supported an important role of mevalonate pathway in regulation of Ca 2+ handling and cardiac dysfunction in HF. However, the in vivo effect of mevalonate pathway inhibition in ischemic-induced contractile dysfunction is still unclear and is the subject of this study.
Together, the available evidence points to a role of the mevalonate pathway in Ca 2+ handling proteins-related cardiac dysfunction.
The aims of this study were to investigate the effects on cardiac dysfunction of antagonizing key targets in mevalonate pathway including 3-hydroxy-3-methylglutaryl-CoA reductase (rosuvastatin), farnesyl pyrophosphate synthase (alendronate), and Rho-kinase (fasudil) in more detail using an in vivo model of ischemic cardiomyopathy. In order to explore the molecular mechanism, our specific focus was to examine alterations in key regulators of Ca 2+ homeostasis including SERCA2a, PLB, PSer16-PLB, RyR2, and FKBP12.6 in the rat myocardium. 
| MATERIALS AND METHODS

| Animal preparation
| Serum lipid measurement
Serum total cholesterol, triglycerides, and low-and high-density lipoprotein cholesterol were measured in a routine diagnostic analyser (Hitachi 7600, Hitachi High-Technologies Corporation, Tokyo, Japan) using enzymatic colorimetric assays before rats were killed.
| Echocardiography
Rats were evaluated 1 day and 10 weeks after operation. Short-and 
| Hemodynamic measurement
Ten weeks after MI, rats were anesthetized, and hemodynamic vari- 
| Weighing of heart and infarct size measurement
After hemodynamic measurement, the blood was withdrawn from carotid artery to separate the serum. Then, we perfused the rats with saline to get rid of blood left in the body to make sure blood will not stay inside the heart. The heart was retrieved, washed with precooled saline.
Left ventricular relative weight (LVRW) was obtained, when the Left ventricular actual weight (LVAW) was corrected by the body weight.
To quantify pulmonary edema, the harvested wet lungs were weighed and heated at 80°C for 3 days in order to determine extravascular lung water by calculating the wet weight/dry weight ratio (W/D). The heart tissue was cut into 5-μm-thick cross-section at the papillary muscle level, fixed in 10% formalin, and then dehydrated and embedded in paraffin. One 5-μm section was obtained from this slice and stained with hematoxylin-eosin. To evaluate the infarct size, triphenyltetrazolium chloride staining (TTC) was performed in control and MI rats. 16 The hearts of the animal were frozen and sliced into five sections perpendicular to the long axis of the heart. Sections were then incubated with 
| Reverse transcription-polymerase chain reaction
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized according to the manufacturer's instructions of the Reverse Transcription kit (Takara Bio Inc., Dalian, China).
Reverse transcription-polymerase chain reaction was performed using
TaqMan gene expression assays (Applied Biosystems, Foster City, CA, USA). The amount of PCR product was determined fluorometrically using the EvaGreen dsDNA quantitation reagent (Biotium, Hayward, CA, USA). We used primers according to the references below:
FKBP12.6, 17 RyR2, and β-actin (β-actin as internal control gene). 18 The fold change of expression in target genes, normalized to β-actin, and relative to normal control, was calculated using the 2 
| Western blotting
Total protein was isolated from LV myocardium by homogenizing myocardial tissue in ice-cold RIPA solubilization buffer (Beyotime, Jiangsu, China) consisting of 1% Triton-X-100, 1% deoxycholate, 0.1% SDS, and 1 mM of PMSF. The lysate was centrifuged. The protein concentration of the supernatant was quantified using a BCA Protein Assay kit (Beyotime). Equal amounts of protein from each sample were separated by 10% SDS-PAGE and electrotransferred to PVDF membranes.
After blocking with 5% nonfat milk, membranes were incubated with primary antibodies against SERCA2a (1:1000 dilution, Thermo The numerical values of SERCA2a, PLB, PSer16-PLB, FKBP12.6, and
RhoA blot bands were semiquantified using Odyssey ® infrared imaging system (LI-COR) and corrected by comparison of glyceraldehyde phosphate dehydrogenase (GAPDH, 36 kDa).
| Statistical analysis
All results were expressed as mean±SD. Statistical analysis was conducted with SPSS version 16.0 software (IBM Corporation, Armonk, NY, USA), using one-way analysis of variance followed by the Dunnett t test to determine significant differences among groups. A value of P<.05 was considered statistically significant.
| RESULTS
| Effects of mevalonate pathway inhibition on serum lipid profile in rats
Ten weeks treatment of rosuvastatin, alendronate, and fasudil did not influence the serum concentrations of total cholesterol, triglycerides, and low-and high-density lipoprotein cholesterol in normal and MI rats ( Table 1) .
| Effects of mevalonate pathway inhibition on ischemia-induced myocardial remodeling
We evaluated the effect of mevalonate pathway inhibition on ischemic-induced myocardial remodeling by LVRW and infarct size determination as well as echocardiography.
Left ventricular relative weight significantly increased in MI rats.
Rosuvastatin and alendronate treatment reduced LVRW, while fasudil failed to decrease LVRW ( 
| Effects of mevalonate pathway inhibition on ischemia-induced myocardial dysfunction
Echocardiographic and hemodynamic analyses of cardiac function as well as W/D ratio determination were carried out at 10 weeks postsurgery in all groups of rats. Our results suggest that 10 weeks after MI, LV FS, LVSP, systolic and diastolic BP, as well as ±dp/dtmax decreased, whereas LVEDP remarkably increased comparing with normal group.
Rats receiving rosuvastatin and alendronate treatment showed a significantly higher FS, LVSP, systolic and diastolic BP, ±dp/dtmax, and lower LVEDP than the MI rats. Fasudil treatment did not result in a significant 
| Effects of mevalonate pathway inhibition on ischemia-induced RhoA protein expression
There was no significant difference in the RhoA expression between normal control and MI groups. RhoA protein levels were depressed in all treatment groups including rosuvastatin, alendronate, and fasudil ( Figure 3 ).
| Effects of mevalonate pathway inhibition on ischemia-induced Ca 2+ handling dysfunction
To explore the possible mechanism why mevalonate pathway inhibition improved ischemia-induced myocardial dysfunction, changes in the expression levels of Ca 2+ regulatory proteins were investigated.
As shown in Figure 2 , the mRNA level of RyR2 and FKBP12. and alendronate, whereas fasudil did not modify RyR2 and FKBP12.6 expression after MI. (Figure 3 ).
| DISCUSSION
In the present study, we further strengthened our assumption that mevalonate pathway inhibition could prevent LV remodeling and dysfunction in a rat model of ischemic cardiomyopathy. Another important finding of this study was that the protective effect of mevalonate pathway inhibitors on cardiac dysfunction was accompanied by restoration of Ca 2+ handling proteins including SERCA2a, PLB, PSer16-PLB, RyR2, and FKBP12.6.
The detailed molecular mechanisms of the pleiotropic effects of statins remain to be fully elucidated. Experimental and clinical research indicated that it may be derived from statin's potent effects on down-regulation of small GTPase signaling pathways through inhibition of isoprenoid intermediate synthesis in mevalonate pathway. 20, 21 However, the cardiovascular pharmacological effects of mevalonate pathway inhibition are limited in experimental studies, and the results are controversial. 22 In the present study, rosuvastatin, alendronate, and fasudil did not lead to a significant change in serum lipid levels, possibly because the lipid levels are relatively low in normal rats, and drugs such as statins do not usually modify the lipid profile in rats. [23] [24] [25] Thus, the beneficial effects of rosuvastatin and alendronate appear to be independent of lipid-lowering.
Our results suggest that 10 weeks after MI, rosuvastatin and alendronate treatment prevented myocardial remodeling and improved cardiac function in rats. However, we did not observe a significant change of the above indices after fasudil treatment. Regarding the infarct size, we found rosuvastatin, alendronate, and fasudil treatment all resulted in significant LV infarct size reduction. These results implicated that rosuvastatin and alendronate have potential pharmaceutic effects on myocardial remodeling and dysfunction. Fasudil could reduce infarct size, but is not effective enough to improve myocardial remodeling and dysfunction.
Ryanodine receptor 2/FK506-binding protein 12.6 complex and SERCA2a/PLB complex are key cardiac Ca 2+ cycling proteins responsible for cardiac contractile dysfunction. 3 We found that rosuvastatin, cardiac function produced by rosuvastatin and alendronate treatment was more pronounced than that observed in the fasudil group. So taken together, the increased expression of RyR2 and FKBP12.6 and the resulting improved myocardial function by FPP inhibition in the rosuvastatin and alendronate groups may be partially mediated through a RhoA-independent mechanism, which is possibly associated with Rasand/or Rac-related downstream signaling pathways.
In vitro and animal studies support a role of Ras in cardiac contractile defects. 26, 27 Research on cellular mechanism has provided ev- The role of RhoA/ROCK in cardiac contraction is controversial.
Some groups have reported that ROCK played positive inotropic effects and increased contraction in the heart. 36 Studies from transgenic mice also supported increased expression of RhoA in myocytes which induced increase in ICa-L density. 37 On the other hand, inhibition of 
| Study limitations
| CONCLUSIONS
In conclusion, the important novel finding of this study is that chronic mevalonate pathway inhibition improved LV remodeling and systolic function and led to amelioration of SR Ca 2+ handling dysregulation supported by restoration of SERCA2a/PLB and RyR2/FKBP12.6 complex expression in a rat model of MI. Our results suggested that the RhoA-independent signaling pathway is involved in the mechanism underlying the mevalonate pathway inhibition in HF and highlighted the therapeutic potential of this pathway.
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